back to search abstracts online
Abstract 643. Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors That Target the gp41 Coiled-Coil Pocket
Abstract 644. Glycosylation-Deficient Mutants of HIV-1 TM
Abstract 645. Determinants of CD4 Independence, Neutralization Sensitivity, and Coreceptor Binding Site Exposure in a CD4-Independent Env Protein
Abstract 646. Changes in SIVmac239 gp120 that Compensate for an Inactivating Mutation in the CD4-Binding Domain
Abstract 647. Analysis of the Interaction between gp120 V3 Region and Coreceptors by Using Chimeric Env-Pseudotyped Viruses (II): Binding of a Chimeric Env to a Non-7 Transmembrane Receptor Can Lead to Viral Entry
Abstract 648. A Novel Restriction to HIV-2 Infection of Cells
Abstract 649. HIV-1 Core Particles Travel on Microtubules to Reach the Nucleus of Infected Cells
Abstract 650. Persistence of Episomal HIV-1 Infection Intermediates in the Face of HAART and Sustained, Undetectable HIV-1 RNA
Abstract 651. CCR5, CXCR4, and CD4 Are Clustered, Closely Apposed, and Concentrated on Microvilli of Human Macrophages and T-Cells as Shown by Immunoelectron Microscopy
Abstract 652. Rapid Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by HAART: A Kinetic Study Using Deuterated Glucose
Abstract 653. Influence of Adjuvant Il-2 Therapy on T Cell Turnover, Activation, and Thymic Recovery: Discordance between Lymphoid Tissue (LT) and Peripheral Blood (PB)
Abstract 654. In Vivo Labeling Studies with Bromodeoxyuridine (BrDU) and 2H-Glucose Demonstrate Differential Effects of HIV on Lymphocyte and Monocyte Proliferation, and Substantially Enhanced Lymphocyte Proliferation in HIV-Infected Patients Receiving IL-2 Therapy
Abstract 655. Immunodominant HIV-Specific CD8+ T Cell Reponses Can Not Be Predicted by MHC Class I Haplotype
Abstract 656. HIV-Specific T Cell Responses in Seronegative Volunteers Immunized with an HIV-1 gag-pol DNA Vaccine
Abstract 657. Frequency and Epitope Specificity of CTL Elicited in Uninfected Recipients of Candidate AIDS Vaccines in AVEG Phase I/II Studies: Comparison with CTL Responses to HIV-1 Infection
Abstract 658. Selection of the K103N Nevirapine Resistance Mutation in Ugandan Women Receiving NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET-006)
Abstract 659. Duration of Ruptured Membranes and Vertical Transmission of HIV-1: A Meta-Analysis from Fifteen Prospective Cohort Studies
Abstract 660. Systemic Pharmacokinetics (PK) of Oral Zidovudine (ZDV) Given during Labor and Delivery to HIV-1-Infected Pregnant Women
Abstract 661. Nelfinavir (NFV) Pharmacokinetics in Combination with Ritonavir (RTV) in Infants and Children with Advanced HIV Disease
Abstract 662. Efavirenz (EFV) Liquid Suspension in Combination with Nelfinavir (NFV) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Children
Abstract 663. Abacavir(ABC)/3TC/ZDV and 3TC/ZDV Reduce CSF HIV-1 RNA in Antiretroviral-Experienced Children
Abstract 664. Antepartum Antiretroviral Therapy and Pregnancy Outcomes in 462 HIV-Infected Women in 1998-1999 (PACTG 367)
Abstract 665. Evaluation of Living Uninfected Children for Mitochondrial Defects: Women and Infants Transmission Study
Abstract 666. Alkylglycerol Foscarnet Analogs Are Active In Vitro at Submicromolar Concentrations against a Panel of Drug-Resistant Strains of HIV-1
Abstract 667. Potency, Breadth, and Durability of the Antiviral Activity of PRO 140, a Novel Inhibitor of CCR5-Mediated HIV-1 Entry
Abstract 668. Anti-HIV Activity and Tolerability of DAPD, a Novel Dioxolane Guanosine RT Inhibitor: Initial Results of a Phase I/II 14-Day Monotherapy Clinical Trial
Abstract 669. Short-Course Monotherapy with AG1549, a Novel Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), in Antiretroviral Naïve Patients
Abstract 670. Dual NNRTI Therapy [MKC-442, Emivirine (EMV) + Efavirenz (EFV)] for Patients Failing PI Regimens: Pharmacokinetics and Short-Term Efficacy
Abstract 671. Antiviral Activity, Safety, and Tolerability of Emivirine (Coactinon, EMV, MKC-442) in a Protease Inhibitor-Sparing Regimen with two Nucleoside Reverse Transcriptase Inhibitors (NRTI) in Treatment Naive Patients: Pooled Analysis of Three Controlled Clinical Trials through 24 Weeks
Abstract 672. Safety and Antiviral Efficacy of a Novel Once-Daily HIV-1 Protease Inhibitor BMS-232632: Preliminary Results from a Phase II Clinical Trial
Abstract 673. The Safety, Efficacy and Viral Dynamics Analysis of Tipranavir, a New-Generation Protease Inhibitor, in a Phase II Study in Antiretroviral-Naive HIV-1-Infected Patients
Abstract 674. Effect of Highly Active Antiretroviral Therapy (HAART) on Cervical Cytologic Changes Associated with Oncogenic HPV among HIV + Women
Abstract 675. Incidence and Progression of Cervical Squamous Lesions among Women with HIV: Insights from the First 13,038 Pap Smears of the Women's Interagency HIV Study
Abstract 676. Longitudinal Assessments of Oral and Vaginal Candida Colonization, Species, and Fluconazole Susceptibility in HIV-Seropositive Women. The HER Study
Abstract 677. Weekly Treatment for Prophylaxis of Candida Vaginitis
Abstract 678. Bacterial Vaginosis Decreases Suppression of Female Genital Tract HIV-1 RNA Levels
Abstract 679. Selection of Drug-Resistant Variants in the Female Genital Tract of Human Immunodeficiency Virus Type-1-Infected Women Receiving Antiretroviral Therapy
Abstract 680. HIV-1 RNA in the Female Genital Tract: Durability of Response to Highly Active Antiretroviral Therapy (HAART)
Abstract 681. Hormonal Levels among HIV-Seropositive Women during the Menstrual Cycle
Abstract 682. Causes and Rates of Death among HIV-Infected Women 1993-1998: The Contribution of Illicit Drug Use and Suboptimal HAART Use
Abstract 683. Quantification of HIV-1 p24 Antigen and Antibody Rivals HIV-1 RNA and CD4+ Enumeration for Prognosis
Abstract 684. Early Plasma HIV Viral Load and Changes in HIV Viral Load over Time in Children with Hemophilia
Abstract 685. Initial Rates of HIV-1 Decline in Blood Plasma as a Major Predictor of Antiretroviral Drug Efficacy
Abstract 686. A Meta-Analysis of Treatment-Mediated Changes in HIV-1 RNA and CD4 Counts as Predictors of Clinical Endpoints in HIV-Infected Children
Abstract 687. Longitudinal Profile of Viral Phenotypes in Vertically HIV-Infected Children with Rapid Disease Progression
Abstract 688. Contrasting Effects of CCR5 delta32 Heterozygosity on HIV-1 Disease Progression in HIV-1-Infected Children with SDF-1 Wild-Type vs. Gene Variant
Abstract 689. Th1/Th2 Cells Influence the Coreceptor Tropism of HIV-1 Isolates
Abstract 690. Trends in the Incidence on AIDS-Defining Conditions (ADCs) Among Children Infected with HIV: 1992-1997
Abstract 691. Impact of Introduction of Protease Inhibitor Therapy on Reductions in Mortality among Children and Youth Infected with HIV-1
Abstract 692. Review of Deaths among a Cohort of New York State (NYS) Infants Exposed in the Perinatal Period to HIV and Antiretroviral Drugs
Abstract 693. A Phase III Study of Amprenavir in Protease-Inhibitor-Naive and -Experienced HIV-Infected Children and Adolescents
Abstract 694. A Randomized Trial of Two Saquinavir (SQV-SGC)-Containing Combination Treatment Regimens in HIV-Infected Children
Abstract 695. A Phase II Study of Amprenavir (APV, 141W94, AGENERASETM) in Antiretroviral-Experienced Children with HIV-Infection
Abstract 696. Long-Term Follow-Up of a Group of HIV-1 Infected Children Initiating HAART Early in Infancy
Abstract 697. Combination Nucleoside Analogs Plus Nelfinavir, Nevirapine, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children
Abstract 698. Viral Load Reduction (VLR) in Children with Advanced HIV Disease Treated with 4-Drug Antiretroviral Treatment (ART) Regimens Including NRTIs, Nevirapine (NVP), Nelfinavir (NFV), and/or Ritonavir (RTV) (PACTG 366)
Abstract 699. Variability in Efavirenz (EFV) Concentrations Predicts Virologic Outcome in HIV-Infected Children
Abstract 700. A Pilot Study of Early Therapy with Abacavir (ABC)/3TC/ZDV in HIV-1-Infected Infants
Abstract 701. rCD4-IgG2 in HIV-1-Infected Children: Phase I/II Study
Abstract 702. HIV-1-Specific T-Helper Cell Responses Detected at Birth: Protection against Intrapartum and Breast Feeding-Associated Transmission of HIV-1
Abstract 704. Follow-up of HIV-1 Markers in Mother/Child Pairs in Cameroon
Abstract 705. Prevention of Mother-to-Child Transmission of HIV by Elective Cesarean Section: Costs, Outcomes, and Cost-Effectiveness
Abstract 706. Increased Use of Maternal Combination Antiretroviral Therapy and Elective Cesarean Section to Reduce Perinatal HIV Transmission in North Carolina
Abstract 707. Trends to Reduce Perinatal HIV Transmission in New York City
Abstract 708. Perinatal HIV Transmission Rates among HIV Infected Pregnant Women in New York State (NYS)
Abstract 709. Association of Maternal ZDV Use during Pregnancy and Infant ZDV Genotypic Resistance with Rapid Disease Progression among Infants in the WITS
Abstract 710. Reproductive Choices and Pregnancy Outcomes after Participation in ACTG 076
Abstract 711. Perinatal HIV Transmission among Women with No Prenatal Care
Abstract 712. Evaluation of Plasma Viral Load for the Establishment of the HIV Infection Status in Brazilian Children Born to Seropositive Women
Abstract 713. Performance Characteristics of HIV-1 Culture, DNA PCR, or Quantitativ RNA for Early Diagnosis of Perinatal HIV-1 Infection
Abstract 714. Placental Transfer of Saquinavir (SQV) Studied in the Human In Vitro Placental Perfusion Model
Abstract 715. PACTG 353 A Phase I Study of Safety, Pharmacokinetics, and Antiviral Activity of Combination Nelfinavir (NFV), ZDV, and 3TC in HIV-Infected Pregnant Women and Their Infants
Abstract 716. Pharmacokinetics of Nevirapine (NVP) in Pregnant Women and in Their Infants Following In Utero Exposure
Abstract 717. Plasma Clearance of Nevirapine Is Increased in Neonates of Mothers Treated with Nevirapine during Pregnancy
Abstract 718. Pharmacokinetics (PK) of Saquinavir (SQV) and Nelfinavir (NFV) in a Twice-Daily (BID) Regimen in HIV-Infected Children
Abstract 719. Efavirenz (EFV) and Nelfinavir (NFV) Pharmacokinetics (PK) in HIV-Infected Children under 2 Years of Age
Abstract 720. Preliminary Analysis of Abacavir Succinate (ABC) Pharmacokinetics in Neonates Differs from Adults and Young Children
Abstract 721. Dapsone Population Pharmacokinetics in HIV-Infected Children
Abstract 722. Cleavage Site Mutations in Patients with HIV Highly Resistant to Several Protease Inhibitors
Abstract 723. Insertions between Codons 35 and 38 of the Protease Gene in HIV-1 Strains from Patients Failing Antiretroviral Therapy
Abstract 724. A Novel Mechanism of HIV Drug Resistance Encoded in p6Gag
Abstract 725. HIV-1 Population Dynamics in Patients Treated with Ritonavir
Abstract 726. Cross-Resistance to Amprenavir in PI-Treated Patients
Abstract 727. Agenerase in Dual PI Combination Therapy with Saquinavir, Indinavir, or Nelfinavir: Emergence of Resistance
Abstract 728. Mutations at Codons 10 and 36 of Protease Region in Absence of Primary Mutations May Correlate with Virological Outcome in Naive Patients Starting a PI-Containing HAART Regimen
Abstract 729. Cross-Resistance to Nelfinavir Can Be Predicted by Previous Antiretroviral Exposure in the Absence of D30N Mutation
Abstract 730. Pretherapy gag/pol HIV-1 Genotype Predicts Viral and Immune Response to Combination Therapy with Protease Inhibitors [PI] in PI-Naive Patients
Abstract 731. Baseline Genotype and Phenotype Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks
Abstract 732. Relationship of Baseline Viral Phenotype and Genotype to RNA Response after Switching from Long-Term Saquinavir (SQVhc) to Indinavir (IDV) or Saquinavir Soft-Gelatin Capsule (SQVsgc) in ACTG 333
Abstract 733. Use of a Recombinant Virus Assay to Determine Stavudine Susceptibility in HIV-1 from Patients Treated with Stavudine Monotherapy
Abstract 734. Mechanism of AZT Resistance Resolved Biochemically: Study of a Panel of Site-Directed HIV-1 Reverse Transcriptase Mutants
Abstract 735. Removal of d4TMP from Blocked Primer/Templates by HIV-1 Reverse Transcriptase-Containing AZT-Resistance Mutations Is Strongly Inhibited by Physiological Concentrations of dNTPs
Abstract 736. Selection of HIV-1 Variants Resistant to Potent Lipid Prodrugs of Phosphonoformic Acid
Abstract 737. In Vivo Selection, Fitness, and Virulence of HIV-1 Resistant to Multiple Nucleoside Analogs
Abstract 738. An Amino Acid Deletion at Codon 67 and a Novel SubstituionT69G in the RT of HIV-1 Confer Multidrug Resistance
Abstract 739. Acquisition of the Q151M Mutation May Occur through a Q151L Intermediate but Requires the Presence of Specific Polymorphisms (S68G) in the Reverse Transcriptase (RT)
Abstract 740A. HIV-1 RT Mutations in Patients After 24 Weeks of Tenofovir Disoproxil Fumarate (formerly PMPA Prodrug) Therapy Added to Stable Background ART
Abstract 740. Common, Rare, and New HIV-1 Resistance Profiles Observed in Routine Clinical Practice: A Survey of over 5,000 Isolates and the Characterization of a Novel 3TC Resistance Mutational Profile Lacking 184V
Abstract 741. Prevalence and Conditions of Selection of 44D and/or 118I RT Mutations in Clinical Practice
Abstract 742. Anti-HIV-1 Activity of 3'-Fluoro-3'-deoxythymidine for Different Multidrug-Resistant Mutants
Abstract 743. Variation in the Rate of Appearance of Lamivudine (3TC) Resistance in HIV-1-Infected Individuals and Its Relationship to Effective Population Size
Abstract 744. Changes in Mutation Patterns of Reverse Transcriptase and Protease Genes in Treated HIV Infected Patients in Marseille Area from 1997 to 1999. A Unique Molecular Mechanism of Resistance to Multiple Dideoxynucleosides provided by MDR Mutations and Insertions/Deletions in the RT Gene.
Abstract 745. Genotyping and Phenotyping Analysis of B and Non-B HIV-1 Subtypes from Patients under HAART
Abstract 746. High Prevalence of Genotypic Antiretroviral (ART) Drug-Resistant HIV-1 Strains among HIV-1-Infected Patients Receiving ART in Abidjan, Ivory Coast
Abstract 747. Prevalence of pol Gene Mutations in a Cohort of Antiretroviral-Naive Patients: Correlation with HIV RNA and CD4 Count at the Time of Genotypic Testing
Abstract 748. Resistance Profiles to Antiretroviral Drugs in HIV-1-Naive Patients
Abstract 749. Primary HIV-1 Resistance in the Province of Ontario
Abstract 750. Comparison of Viral Resistance Emerging over 48 Weeks of Therapy with IDV/COM vs. ABC/COM
Abstract 751. Genotypic and Phenotypic Analysis of HIV-1 from Patients Receiving Combination Therapy Containing Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), a Protease Inhibitor and Emivirine (EMV, Coactinon)
Abstract 752. Genotypic Characterization of Resistance in Patients Failing an EFV/ IDV/ NRTI Regimen (Study DMP266-020)
Abstract 753. Characterization of Altered Phenotypic Antiretroviral (ARV) Susceptibility to Drugs in a Failing Regimen
Abstract 754. Viral Evolution in Children with Plasma HIV-1 RNA Levels <50 copies/ml
Abstract 755. Continued Low Morbidity and Mortality among Patients with Advanced HIV Infection and Their Patterns of Highly Active Antiretroviral Therapy (HAART) Usage
Abstract 756. Comparative Effects on Clinical Disease Progression of d4T- vs. ZDV-Containing Regimens in the CHORUS Observational Cohort
Abstract 757. EuroSIDA: Temporal Changes in Response to HAART
Abstract 758. Correlates of Durable Treatment Success among Long-Term Highly Active Antiretroviral (HAART) Recipients in the HIV Outpatient Study (HOPS)
Abstract 759. Effectiveness of Highly Active Antiretroviral Therapy (HAART) in Veterans Affairs Medical Centers (VAMC) from 1996 - 1999
Abstract 760. Substance Abuse and Mental Health Disorders in a National HIV-Infected Sample: Effect on Use and Type of Antiretroviral Therapy
Abstract 761. Incremental Costs of HIV Suppression in HIV Therapeutic Failure
Abstract 762. Patterns and Prognostic Implications of Prior Antiretroviral Therapy (ART) at UCSD Owen Clinic: 1996-1999
Abstract 763. Detection of Divergent Human and Simian Immunodefiency Viruses Using a Generic env Peptide-Based Enzyme Immunoassay and Rapid Tests
Abstract 764. Evaluation of a Rapid Test for Detection of HIV-1/2 Saliva Antibodies in a Cohort of Patients from Brazil, India, and the United States
Abstract 765. Evaluation of Rapid HIV Testing Platforms
Abstract 766. Evaluation of the Merlin Immediate HIV-1 and -2 Test for HIV Antibody Performed at Point-of-Care (POC)
Abstract 767. Evaluation of a Sensitive/Less-Sensitive Testing Algorithm to Detect Recent Infection among Persons Infected with HIV-1 Subtypes B or E in Thailand
Abstract 768. Development of Less Sensitive Anti-HIV1 EIA Protocols to Detect Early HIV-1 Infection Using 96 Well-Formatted HIV-1 EIA Kits
Abstract 769. Development of a Novel Assay to Measure Antigen-Specific Immune Responses to Multivalent Vaccines for HIV-1
Abstract 770. Early Detection of HIV Infection in Infants in Thailand, Using Dried Blood Spots (DBS) and Roche AMPLICOR HIV-1 Assay Using 1.5 Primers
Abstract 771. Evaluation of HIV TaqMan: Comparison with Amplicor HIV-1 Monitor
Abstract 772. Evaluation of the Limit of Detection, Dynamic Range, and Precision of the COBAS AMPLICOR and AMPLICOR HIV-1 Monitor, Version 1.5 Tests
Abstract 773. Performance Characteristics of the bDNA 3.0 Assay for Quantitation of HIV-1 RNA in Plasma
Abstract 774. Variation in HIV RNA Assays at Low RNA Concentration
Abstract 775. Improved Conditions for Extraction and Amplification of Human Immunodeficiency Virus Type 1 RNA from Plasma Samples with Low Viral Load
Abstract 776. HIV-1 RNA Testing by bDNA and PCR in Asymptomatic Patients after Sexual Exposure to HIV
Abstract 777. Quantification of HIV-1 Group O Virus Isolates Using the Hybrid Capture II HIV RNA v1.0 Test and Other Conventional Methods
Abstract 778. Real-Time Detection of Group O HIV-1 and HIV-2 RNA by PCR
Abstract 779. Efficient Quantification of HIV-1 Viral Isolates (Group M Subtypes A-G and Group O) by the Abbott LCx HIV RNA Quantitative Assay
Abstract 780. Evaluation of the Gen-Probe HIV-1 Viral Load Assay with Kenyan Subtype Samples
Abstract 781. Detection of Diverse Variants of HIV-1 Groups M, N, and O and Simian Immunodeficiency Viruses from Chimpanzees Using Generic pol and env Primer Pairs
Abstract 782. Use of Calibrated Viral RNA Standards to Assess the Performance of HIV-1 RNA Quantitation Tests
Abstract 783. HIV/SIV Viral Detection by In Situ NASBA
Abstract 784. Persistence of Intracellular HIV-1 mRNA (In Cell Viral Load) Correlates with HIV-Specific Immune Responses in HIV Infected Subjects on Stable HAART Therapy
Abstract 785. Quantitative Differences in Viral Replication in Blood vs. Lymph Nodes in Asymptomatic HIV-1-Infected Patients
Abstract 786. Impact of Phenotypic Antiretroviral Drug Resistance Testing on the Response to Salvage Antiretroviral Therapy (ART) in Heavily Experienced Patients
Abstract 787. The Relationship between Genotypic Resistance Mutations in RT and PR and Virological Response to Combination Therapy in a Clinical Cohort
Abstract 788. Potential Clinical Impact of Small Differences between Virco Antivirogram and ViroLogic PhenoSense Assays for Abacavir in 3TC Experienced Patients
Abstract 789. Budget Impacts of the Integration of Genotypic Antiretroviral Resistance Testing (GART) into HIV Treatment Guidelines
Abstract 790. A Rapid and Inexpensive Approach for Phenotypic Analysis of Drug Resistance to Reverse Transcriptase (RT) Inhibitors by Direct Analysis of RT Activity in Plasma
Abstract 791. Sequencing by Hybridization vs. Cycle Sequencing for Genotyping HIV-1 Reverse Transcriptase
Abstract 792. Proficiency Testing of Sequence-Based Genotypic Assays
Abstract 793. The Accuracy and Reproducibility of High-Throughput Genotypic and Phenotypic HIV-1 Resistance Testing under EN45001 and CLIA Accreditation Labels
Abstract 794. Development of a Microarray-Based HIV-1 Drug Resistance/Genotyping Assay
Abstract 795. Comparison of HIV Genotypic Resistance Testing in Plasma and PBMCs during Low-Level Viremia
Abstract 796. A Dose-Escalating Study of the Concomitant Intramuscular Administration of Two Facilitated DNA Plasmid Vaccines Containing HIV-1 env/rev and gag/pol Genes in HIV-Infected Patients Also Receiving Highly Active Therapy
Abstract 797. Induction of HIV-1 Gag-Specific T Cells and B Cells in Rhesus Monkeys Immunized with Plasmid DNA or p55gag Protein-Based Vaccines
Abstract 798. Increased Expression Efficiency and Immunogenicity of Sequence Modified HIV-1 gag Gene
Abstract 799. Design and Construction of Novel Envelope Genes from the HIV-1SF162 Isolate for Use in DNA Vaccines and Production of Protein Vaccines
Abstract 800. Induction of Lymphoproliferative and Antibody Responses in Baboons, Using a DNA Prime/Protein Boost Vaccine Regimen
Abstract 801. Vaccination of Seronegative Volunteers with an HIV-1 env/rev DNA Vaccine Induces Antigen-Specific Cellular Immune Responses
Abstract 802. Cationic Microparticles: A Potent Delivery System For DNA Vaccines
Abstract 803. Codon Optimization for High-Level Expression of HIV-1 Subtype-C Envelope Glycoprotein In Vitro
Abstract 804. Noninvasive Monitoring of Gene Delivery Using Vaccines
Abstract 805. Bacterial Transduction with Attenuated Salmonella typhimurium as a Vaccine Strategy against AIDS
Abstract 806. Attenuated Listeria monocytogenes Expressing HIV Gag or Nef Elicit- Human HIV-Specific CD4 and CD8 T Cell Responses
Abstract 807. Induction of SIV-Specific Cellular Immune Responses by Using Recombinant Sendai Viral Vector
Abstract 808. Recombinant Fowlpox Virus Vectors Encoding HIV-1 Gag/Pol with Human Interferon-g Stimulate CTL Responses: Implications for HIV Therapeutic Vaccines
Abstract 809. Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1
Abstract 810. Protection by a Confined Live Vaccine against Simian Immunodeficiency Virus Challenge
Abstract 811. SIV-Specific CTL and Protection against Challenge in Rhesus Macaques Immunized with a Live Attenuated Simian Immunodeficiency Virus Vaccine
Abstract 812. Predicting the Epidemiological Consequences of Live Attenuated Vaccines in Developing Countries
Abstract 813. Neutralizing Antibody Responses in Humans and Animals Immunized with Intra-Subtype B Bivalent Vaccine AIDSVAX B/B
Abstract 814. An SIV C4 Peptide Subunit Vaccine May Enhance Viral Burden in Rhesus Macaques after Intrarectal Challenge with SIVmac251
Abstract 815. Genetically Modified Anthrax Toxin Proteins Encoding HIV Antigens Are Attractive Candidates for an HIV Vaccine Designed to Induce T Cell Immunity
Abstract 816. Modification of HIV-1 Nef Protein for HIV-1 Vaccine Design
Abstract 817. Willingness to Volunteer in Future Preventive HIV Vaccine Trials: Issues and Perspectives from Three U.S. Communities
Abstract 818. Association of HLA Class I Alleles with Cytotoxic T-Lymphocyte (CTL) Responses to Gag and Env in Recipients of ALVAC-HIV Canarypox Vaccines
Abstract 819. Correlation of Vaccine-Induced Cross-Tropic In Vitro Resistance to HIV-1BaL with CTL Activity
Abstract 820. The M184V Mutation of SIV RT Delays Reversion of Live-Attenuated SIV Containing Deletions in the Noncoding Region
Abstract 821. The Evolution of the Nef Gene in Attenuated and Wild-Type SIVmac-Infected Macaques
Abstract 822. Induction of High-Avidity Antibodies and R5 Primary Isolate Neutralizing Antibody Response after Immunization with Oligomeric HIV-1 Envelope Glycoprotein from the Primary R5 Subtype B Strain, HIV-1US4
Abstract 823. Rational Design of Multivalent gp120 HIV-1 Vaccines for Use in Phase III Clinical Trials
Abstract 824. Introducing a Stabilizing Disulfide Bond between HIV-1 gp120 adn gp41 Creates an Antigenic Mimic of the Native Envelope Glycoprotein Complex
Abstract 825. Characterization of Human V3-Specific Antibodies That Neutralize Primary HIV-1 Isolates
Abstract 826. Production and Characterization of Purified gp120-CD4-CCR5 (CXCR4) Complexes for Use as HIV-1 Vaccines and Model Systems
Abstract 827. Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody (NAb) to Subtype E HIV-1
Abstract 828. Generation of Cross-Reactive Neutralizing-Antibody Responses in Rhesus Macaques Immunized with the SF162DV2 Envelope
Abstract 829. Efficacy of Post-Infection Passive Immunization with Purified SIVIG
Abstract 830. Dendritic Cells Infected with Recombinant Canarypox Virus Induce Potent Anti-HIV Cytolytic and Helper T Cell Responses from Chronically Infected Individuals
Abstract 831. Infection of Dendritic Cells with HIV-1 and HIV-1 Antigen Presentation to CD4 and CD8 T Cells from HIV-1-Infected Individuals
Abstract 832. Presentation of SIVgag to Monkey CD8+ and CD4+ T Cells by Using Dendritic Cells Transfected with a Recombinant Adenovirus
Abstract 833. Dendritic Cell-Mediated Genetic Immunization Induces Vigorous T-Helper and CTL Responses In Vitro and in Primates
Abstract 834. Restoration of Anti-HIV-1 CD8+ T Cell Responses during Potent Antiretroviral Drug Therapy by Stimulation with Antigen-Loaded Dendritic Cells
Abstract 835. Analysis of CD11c+ and CD11c- Blood Dendritic Cells and Correlation with Th1/Th2 Cytokine Profile in HIV-1-Infected Patients
Abstract 836. Differential Coreceptor Expression within CD45RA+ and CD45RO+ CD4+ T Cells Provides Distinct Cellular Niches for Independent Non-Syncytium-Inducing HIV-1 Evolution
Abstract 837. Signaling through CD30 Differentially Affects HIV-1 X4 and R5 Replication in TH1/TH2 Polarized Cells
Abstract 838. High Pathogenicity of Mono- and Dualtropic HIV-1 Variants in Human Lymphoid Tissue Is Associated with the Use of CXCR4
Abstract 839. Enhanced CCR5 and CXCR4 Expression on Naive CD4+ T Cells from HIV-1-Infected Subjects
Abstract 840. Pathogenesis of Primary R5 HIV-1 Clones in SCID-hu Mice
Abstract 841. Coreceptor/CD4 Ratios Correlate with HIV Plasma and Cellular Viral Load in Lymph Nodes (LN) and Peripheral Blood (PB) of HIV Infected Individuals
Abstract 842. Target T-Cell Depletion in Human Lymphoid Tissue Dictated by HIV-1 Coreceptor Preferences
Abstract 843. Coreceptor Preference as a Key Determinant of Pathogenesis by HIV-1 and HIV-2 in Lymphoid Tissues Ex Vivo
Abstract 844. Coreceptor Utilization of HIV-1 Primary Isolates during Acute Infection
Abstract 845. Evolution of Dual-Tropic SIV Using CCR5 and CXCR4 as Coreceptor
Abstract 846. CXCR4 Mediates Direct Killing of CD4+ and CD8+ T Cells by HIV Envelope
Abstract 847. Emergence of CXCR4-Tropic env V3 Sequences in HIV-1 RNA during Antiretroviral Therapy Is Associated with Loss of HIV Compartmentalization in the Male Genital Tract
Abstract 848. CD8+ Cytotoxic T Cells Are Target of HIV Infection In Vivo
Abstract 849. Infection of Natural Killer Cells by R5 and X4 HIV-1 Strains
Abstract 850. Evidence for Replication-Competent HIV-1 on Circulating B Cells of Chronically Infected Individuals
Abstract 851. Relationship of CCR5 and SDF-1 Allelic Frequencies to HIV-1 Disease Stage, Viral Load, CD4 T Cell Count, and Progression to AIDS Dementia Complex (ADC)
Abstract 852. The SDF1-3'A Genotype Associates with Accelerated Time to Death from AIDS Diagnosis. Role of CD4+ T Cell Counts
Abstract 853. Homozygous Mutations in 3'A SDF-1 Are Associated with More Rapid Disease Progression
Abstract 854. Genetic Restriction of HIV-1 Infection and AIDS by Promoter Alleles of Interleukin 10
Abstract 855. Population-Level Protection Attributable to Host Genetic Markers Conferring Resistance to AIDS Progression
LB1 A Potential Role for IL-7 in T-Cell Homeostasis in HIV Infected Patients.
LB2 Documentation of HIV-1 Superinfection and Acceleration of Disease Progression.
LB3 Rapid Progression to AIDS among HIV+ Individuals with an Allelic Variant of the CX3CR1 Chemokine Receptor.
LB4 HLA-Bw4 Homozygosity Is Associated with Profound Suppression of HIV-1 Viremia and Long-Term Non-Progression to AIDS.
LB5 It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART: Results from Eight Prospective European Cohorts.
LB6 Pharmacokinetic Interactions between Protease Inhibitors and Selected HMG-CoA Reductase Inhibitors.
LB7 A Randomized, Placebo-Controlled Trial of Saquinavir, Indinavir or Nelfinavir in Combination with Amprenavir, Abacavir, Efavirenz and Adefovir in Patients with Protease Inhibitor Failure.
LB8 A Pilot, Multicenter, Double-Blind, Randomized Study of MK-944A q.d. or b.i.d. vs. Crixivan, All in Combination with Stavudine and Lamivudine.
LB9 Novel Amino Acid Change Influencing Susceptibility to Nevirapine Detected in Primary HIV Infection.
LB10 Virologic and Immunologic Evaluation of Structured Treatment Interruptions in Patients Experiencing Long-Term Virologic Failure.
LB11 Structured Cyclic Antiretroviral Therapy Interruption in Chronic Infection May Induce Immune Responses Against HIV-1 Antigens Associated with Spontaneous Drop in Viral Load.
LB12 Discontinuation of HAART After a Course of Therapeutic Vaccination with ALVAC1452 and rgp160 May Be Associated with Delayed Viral Rebound Kinetics.
L7 Critical Issues in Antiretroviral Therapy
L8 The T Lymphocyte Response to HIV Infection
© 7th Conference on Retroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health
